{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Participants": {
        "score": 2,
        "evidence": "545 patients with clinical stage IA LUL adenocarcinoma who underwent surgery between January 2018 and May 2022"
      },
      "Intervention": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to develop and validate a nomogram to predict high-risk pathology in clinical stage IA lung adenocarcinoma located in the left upper lobe (LUL)"
      },
      "Method_Outcome": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "The cohort was randomly divided into training (80%) and validation (20%) sets"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "545 patients with clinical stage IA LUL adenocarcinoma who underwent surgery between January 2018 and May 2022"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "The nomogram demonstrated excellent discriminative ability, with AUCs of 0.837 in the training set and 0.865 in the validation set"
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 8,
    "max_score": 25
  },
  "model": "gpt-4o"
}